Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | IDH1 R132L |
Gene Variant Detail | |
Relevant Treatment Approaches | IDH Inhibitor (Pan) IDH1 Inhibitor |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06161974 | Phase II | Olutasidenib + Temozolomide | Study of Olutasidenib and Temozolomide in HGG | Not yet recruiting | USA | NLD | GBR | DEU | CAN | AUS | 0 |
NCT03953898 | Phase II | Olaparib | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | Active, not recruiting | USA | 0 |
NCT04056910 | Phase II | Ivosidenib + Nivolumab | Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors | Completed | USA | 0 |
NCT04164901 | Phase III | Vorasidenib | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | Active, not recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | 1 |
NCT05876754 | Phase III | Ivosidenib | An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe) | Recruiting | SWE | ROU | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 2 |
NCT05921760 | Phase Ib/II | Ipilimumab + Ivosidenib + Nivolumab | Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma | Active, not recruiting | USA | GBR | 0 |
NCT06127407 | Phase III | Ivosidenib | Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER) | Recruiting | USA | CAN | BRA | AUS | 1 |
NCT04088188 | Phase I | Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | Terminated | USA | 0 |